Literature DB >> 1915408

Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

M Akova, H E Akalin, O Uzun, D Gür.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1915408     DOI： 10.1007/bf01967286

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Failure of fluconazole therapy in Candida krusei fungemia.

Authors:  B L Røder; C Sonnenschein; S H Hartzen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  Prophylaxis of oropharyngeal candidiasis with fluconazole.

Authors:  G Samonis; K Rolston; C Karl; P Miller; G P Bodey
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

Review 3.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors:  M A Fisher; S H Shen; J Haddad; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole.

Authors:  F Meunier; M Aoun; M Gerard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr
  5 in total
  23 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Susceptibility of yeasts to fluconazole.

Authors:  M Scheven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

3.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 4.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 5.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays.

Authors:  K Venkateswarlu; D W Denning; N J Manning; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

Authors:  O Uzun; S Kocagöz; Y Cetinkaya; S Arikan; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.